ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

treprostinil

Also written as “Inhaled Treprostinil”, “treprostinil diethanolamine” and “Oral Treprostinil”.

Its studies are mostly in Pulmonary Arterial Hypertension · Hypertension, Pulmonary · Scleroderma, Systemic · Idiopathic Pulmonary Fibrosis · Chronic Limb-Threatening Ischemia, led by 5 companies.

Drug pageTreprostinil: every studyMany companies study it; this page follows only the 71 they lead. All 99 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Apr 14, 200371 company-led studies, 9 open or runningNext primary completion: Feb 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
United Therapeutics625 open or runningphase 4since Apr 14, 2003Oct 18, 1999Nov 2027phase 3 · NCT05943535
Liquidia Technologiesits history only64 open or runningphase 4since Aug 7, 2026Jan 3, 2018Feb 2027phase 2 · NCT07748000
Mannkindits history only10 open or runningphase 1since Mar 1, 2018Mar 1, 2018none ahead
Pharmosa Biopharmits history only10 open or runningphase 1since Jul 23, 2019Jul 23, 2019none ahead
SciPharm SàRLits history only10 open or runningphase 3since Aug 12, 2011Aug 12, 2011none ahead

Also a collaborator on its studies: PPD Development, LP, Nuventra, FGK Clinical Research and CVie Therapeutics.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of United Therapeutics only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Before these, 44 studies since May 19, 2003.

  1. Jan 6, 2017Phase 2 study in Pulmonary Arterial HypertensionNCT03016468
  2. Jan 27, 20173 phase 3 studiesNCT03055234, NCT03037580, NCT03043651
  3. Feb 9, 2017Phase 4 study in Pulmonary Arterial HypertensionNCT03055221 · 20 enrolled
  4. Mar 20, 2018Phase 4 study in Pulmonary Arterial HypertensionNCT03497689 · 36 enrolled · United States
  5. Mar 29, 2018Phase 3 study in Hypertension, PulmonaryNCT03496623 · 188 enrolled · United States, Argentina, Israel and more
  6. Jan 2, 2019Phase 3 study in Hypertension, PulmonaryNCT03794583 · 41 enrolled · United States, Israel, Italy
  7. May 9, 2019Phase 1 study in Pulmonary Arterial HypertensionNCT03950739 · 51 enrolled · United States
  8. Jun 9, 2019Named treprostinilINNProposed as its International Nonproprietary Name in WHO's List 121
  9. Jan 12, 2021Phase 3 study in Idiopathic Pulmonary FibrosisNCT04708782 · 598 enrolled · United States, Canada, Chile
  10. May 20, 2021Phase 3 study in Idiopathic Pulmonary FibrosisNCT04905693 · 1,850 planned · United States, Argentina, Australia and more
  11. Jan 10, 2022Phase 4 study in Pulmonary Arterial HypertensionNCT05203510 · 52 enrolled · United States
  12. Feb 15, 2022Phase 3 study in Idiopathic Pulmonary FibrosisNCT05255991 · 597 enrolled · Argentina, Australia, Belgium and more
  13. Jul 5, 2023Phase 3 study in Lung Diseases, InterstitialNCT05943535 · 698 planned · United States, Argentina, Australia and more
  14. Oct 19, 2026Phase 2 study in Hypertension, PulmonaryNCT07923591 · 40 planned · United States
  15. Oct 19, 2026Phase 3 study in Hypertension, PulmonaryNCT07923526 · 400 planned · United States

Ahead

  1. Nov 2027Primary completion: phase 3 study in Lung Diseases, InterstitialNCT05943535
  2. May 2028Primary completion: phase 2 study in Hypertension, PulmonaryNCT07923591
  3. Dec 2029Primary completion: phase 3 study in Idiopathic Pulmonary FibrosisNCT04905693
  4. Sep 2034Primary completion: phase 3 study in Hypertension, PulmonaryNCT07923526

TargetBeta

PTGIR →read by rule
“Prostanoid IP receptor agonist; Prostanoid IP receptor agonist; Prostanoid IP receptor agonist”ChEMBL 37, by rule

Other programs on PTGIR

ProgramCompanyFurthest phaseStudies
selexipagruleJohnson & Johnsonphase 423

Studies

The newest 60 of 62 United Therapeutics leads. Each opens its study page. Every study on its drug page →

StudyPhaseStatusPrimary completionSize
NCT07923591Hypertension, Pulmonary · United States2Not yet recruitingMay 202840
NCT07923526Hypertension, Pulmonary · United States3Not yet recruitingSep 2034400
NCT05943535Lung Diseases, Interstitial · United States, Argentina, Australia and more3RecruitingNov 2027698
NCT05255991Idiopathic Pulmonary Fibrosis · Argentina, Australia, Belgium and more3CompletedJun 30, 2025597
NCT05203510Pulmonary Arterial Hypertension · United States4Active, not recruitingApr 30, 202652
NCT04905693Idiopathic Pulmonary Fibrosis · United States, Argentina, Australia and more3By invitationDec 20291,850
NCT04708782Idiopathic Pulmonary Fibrosis · United States, Canada, Chile3CompletedFeb 2, 2026598
NCT03950739Pulmonary Arterial Hypertension · United States1CompletedAug 22, 202351
NCT03794583Hypertension, Pulmonary · United States, Israel, Italy3TerminatedNov 29, 202241
NCT03496623Hypertension, Pulmonary · United States, Argentina, Israel and more3TerminatedOct 13, 2022188
NCT03497689Pulmonary Arterial Hypertension · United States4CompletedMay 11, 202236
NCT03055221Pulmonary Arterial Hypertension4CompletedFeb 25, 201420
NCT03043651Hypertension, Pulmonary · United States3TerminatedMar 2, 202048
NCT03055234Pulmonary Hypertension Associated With Sickle Cell Disease3WithdrawnDec 20210
NCT03037580Hypertension, Pulmonary · United States3TerminatedDec 3, 201984
NCT03016468Pulmonary Arterial Hypertension2WithdrawnSep 20180
NCT03012646Hypertension, Pulmonary2WithdrawnApr 20190
NCT02999906Pulmonary Arterial Hypertension3WithdrawnDec 20210
NCT02893995Pulmonary Arterial Hypertension · China4WithdrawnApr 20180
NCT02882126Pulmonary Arterial Hypertension · China4WithdrawnJun 20210
NCT02847260Pulmonary Arterial Hypertension4CompletedMar 201439
NCT02633293Hypertension, Pulmonary · United States, Puerto Rico3TerminatedAug 1, 2021243
NCT02630316Hypertension, Pulmonary · United States, Puerto Rico3CompletedDec 26, 2019326
NCT02603068Hypertension, Pulmonary · United States2WithdrawnApr 20180
NCT02276872PAH · United States2CompletedJul 20, 201732
NCT02318758Healthy · United States1CompletedOct 201432
NCT02261883Persistent Fetal Circulation Syndrome · United States2TerminatedSep 27, 202242
NCT01934582Pulmonary Arterial Hypertension · United States3CompletedNov 201313
NCT01884038Reperfusion Injury · United States3WithdrawnJun 20100
NCT01746485Healthy · United States1CompletedJul 201219
NCT01557660Pulmonary Arterial Hypertension3WithdrawnDec 20180
NCT01557647Pulmonary Arterial Hypertension3WithdrawnDec 20150
NCT01560637Pulmonary Arterial Hypertension · United States, Argentina, Australia and more3CompletedAug 12, 2021471
NCT01560624Pulmonary Arterial Hypertension · United States, Argentina, Australia and more3CompletedJun 24, 2018690
NCT01588405Pulmonary Arterial Hypertension · United States2CompletedJul 201433
NCT01477333Pulmonary Arterial Hypertension · United States2CompletedNov 201318
NCT01172496Pulmonary Arterial Hypertension · United States1CompletedAug 201024
NCT01165476Pulmonary Arterial Hypertension · United States1CompletedAug 201064
NCT01153386Pulmonary Arterial Hypertension · United States1CompletedAug 201036
NCT01131845Pulmonary Arterial Hypertension · United States1CompletedSep 201016
NCT01104870Hypertension, Pulmonary · United States2CompletedJan 201350
NCT01027949Pulmonary Arterial Hypertension · United States, Australia, Austria and more3CompletedFeb 12, 2020894
NCT00963027Hypertension, Pulmonary · United States1CompletedOct 200930
NCT00963001Hypertension, Pulmonary · United States1CompletedNov 200932
NCT00887978Hypertension, Pulmonary · United States, Belgium, Canada and more3CompletedJul 2011310
NCT00848939Scleroderma, Systemic · United States1CompletedJan 201028
NCT00848107Scleroderma, Systemic · United States, Canada, United Kingdom2TerminatedSep 2011115
NCT00775463Scleroderma, Systemic · United States, Canada, United Kingdom2CompletedMar 2011148
NCT00760916Hypertension, Pulmonary · United States, Australia, Mexico3WithdrawnJan 20090
NCT00741819Pulmonary Arterial Hypertension · United States4CompletedMar 201073
NCT00643604Hypertension, Pulmonary · United States4TerminatedJan 20107
NCT00494533Pulmonary Arterial Hypertension · India4TerminatedOct 200545
NCT00458042Hypertension, Pulmonary · United States4Terminated10
NCT00439946Pulmonary Arterial Hypertension · United States4TerminatedSep 20098
NCT00373360Hypertension, Pulmonary · United States4CompletedJan 200810
NCT00325442Hypertension, Pulmonary · United States, Australia, Austria and more3CompletedSep 2008354
NCT00325403Hypertension, Pulmonary · United States, Austria, Belgium and more3CompletedApr 2011349
NCT00147199Hypertension, Pulmonary · United States, Austria, Belgium and more3CompletedOct 2007235
NCT00067041Peripheral Vascular Diseases · United States3TerminatedDec 200330
NCT00060996Chronic Limb-Threatening Ischemia · United States3TerminatedSep 200430

How it is read

Names in the registry

  • “Inhaled Treprostinil”, 7 entries
  • “treprostinil diethanolamine”, 6 entries
  • “Oral Treprostinil”, 5 entries
  • “treprostinil sodium”, 5 entries
  • “UT-15C SR”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.